Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?

Lancet Respir Med. 2019 Apr;7(4):291-292. doi: 10.1016/S2213-2600(19)30043-8. Epub 2019 Mar 12.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Carcinoma, Non-Small-Cell Lung*
  • Humans
  • Lung Neoplasms*
  • Programmed Cell Death 1 Receptor

Substances

  • Antibodies, Monoclonal, Humanized
  • Programmed Cell Death 1 Receptor
  • pembrolizumab